|
US5376645A
(en)
*
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5262404A
(en)
*
|
1990-02-15 |
1993-11-16 |
The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation |
Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
|
|
EP0485614B1
(de)
|
1990-05-21 |
1997-08-13 |
Toppan Printing Co., Ltd. |
Cyclodextrinderivat
|
|
JP2556236B2
(ja)
*
|
1991-08-29 |
1996-11-20 |
田辺製薬株式会社 |
β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
|
|
YU48722B
(sh)
*
|
1991-10-16 |
1999-07-28 |
Schering Corporation |
Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika
|
|
DE4204315A1
(de)
*
|
1992-02-13 |
1993-08-19 |
Consortium Elektrochem Ind |
Cyclodextringlycoside und verfahren zu ihrer herstellung
|
|
US5403828A
(en)
*
|
1992-08-13 |
1995-04-04 |
American Maize-Products Company |
Purification of cyclodextrin complexes
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
DE4309579C3
(de)
*
|
1993-03-24 |
2000-01-27 |
Sanol Arznei Schwarz Gmbh |
Pharmazeutische Zusammensetzung in Form einer Packung
|
|
DE4313408A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Cyclodextrin-Biocid-Komplex
|
|
HU213200B
(en)
*
|
1993-05-12 |
1997-03-28 |
Chinoin Gyogyszer Es Vegyeszet |
The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
|
|
CZ306394A3
(en)
*
|
1993-12-14 |
1995-08-16 |
Lilly Co Eli |
Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
|
|
US5443824A
(en)
*
|
1994-03-14 |
1995-08-22 |
Piacquadio; Daniel J. |
Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
|
|
DE4429229A1
(de)
*
|
1994-08-18 |
1996-02-22 |
Consortium Elektrochem Ind |
Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
|
|
EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
|
BE1008978A5
(fr)
*
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
DE19505263A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
|
WO1996041646A2
(en)
*
|
1995-06-13 |
1996-12-27 |
Dyer, Alison, Margaret |
Pharmaceutical compositions containing lornoxicam and cyclodextrin
|
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
|
HUT75956A
(en)
*
|
1995-11-29 |
1997-05-28 |
Cyclolab |
Pharmaceutical composition containing thyroxine
|
|
GB9605705D0
(en)
|
1996-03-19 |
1996-05-22 |
Pfizer Ltd |
Therapeutic agents
|
|
WO1997039761A1
(en)
|
1996-04-19 |
1997-10-30 |
Alpha Therapeutic Corporation |
A process for viral inactivation of lyophilized blood proteins
|
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
|
ATE305301T1
(de)
*
|
1996-11-05 |
2005-10-15 |
Childrens Medical Center |
Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
|
|
KR100435426B1
(ko)
*
|
1996-11-29 |
2004-08-16 |
주식회사 포스코 |
구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
|
|
KR100411289B1
(ko)
*
|
1996-11-29 |
2004-02-14 |
주식회사 포스코 |
회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
|
|
DE19713092A1
(de)
*
|
1997-03-27 |
1998-10-01 |
Wacker Chemie Gmbh |
Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
RU2173172C2
(ru)
*
|
1997-05-05 |
2001-09-10 |
Сайдекс Инк. |
Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
|
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
JP4439596B2
(ja)
*
|
1997-06-13 |
2010-03-24 |
サイデクス ファーマシューティカルズ、 インク. |
長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
|
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
|
EP0889056B1
(de)
*
|
1997-07-01 |
2006-04-12 |
Pfizer Products Inc. |
Verfahren zur Herstellung von einem Cyclodextrin
|
|
US6391862B1
(en)
*
|
1997-10-14 |
2002-05-21 |
The Texas A&M University System |
Chiral resolving agents for enantioseparations
|
|
US6699849B1
(en)
*
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
|
EP1067942A1
(de)
*
|
1998-02-23 |
2001-01-17 |
Cyclops, EHF. |
Hochenergetische cyclodextrinkomplexe
|
|
US6048736A
(en)
*
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
DE19825486C2
(de)
*
|
1998-06-08 |
2000-07-06 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
|
|
NZ330726A
(en)
*
|
1998-06-18 |
2000-10-27 |
Dec Res |
Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
|
|
CA2342797A1
(en)
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
|
US20020198174A1
(en)
*
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
US20040152664A1
(en)
*
|
1998-09-02 |
2004-08-05 |
Allergan, Inc. |
Prednisolone compositions
|
|
CZ20012601A3
(cs)
*
|
1999-01-21 |
2002-05-15 |
Bristol-Myers Squibb Company |
Komplex inhibitoru ras-farnesyltranferasy a sulfobutylether-7beta-cyklodextrinu nebo 2-hydroxypropyl-beta-cyklodextrinu a způsob
|
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
|
DE19939662A1
(de)
|
1999-08-20 |
2001-02-22 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
|
|
GB9921958D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
|
|
GB9921954D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
|
|
RU2163120C1
(ru)
*
|
1999-10-12 |
2001-02-20 |
Новосибирский медицинский институт |
Конъюгат изониазид-декстран и его применение в качестве противотуберкулезного препарата
|
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
|
US6677256B1
(en)
|
1999-12-28 |
2004-01-13 |
Kimberly-Clark Worldwide, Inc. |
Fibrous materials containing activating agents for making superabsorbent polymers
|
|
MXPA02006537A
(es)
*
|
1999-12-28 |
2002-12-09 |
Kimberly Clark Co |
Polimeros superabsorbentes.
|
|
SK282717B6
(sk)
*
|
2000-03-10 |
2002-11-06 |
�Stav Experiment�Lnej Farmakol�Gie Sav |
Spôsob prípravy ultravysokomolekulových hyalurónanov
|
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
|
CN1439023A
(zh)
*
|
2000-04-28 |
2003-08-27 |
国立爱尔兰都柏林大学 |
两亲大环衍生物及其类似物
|
|
ATE416791T1
(de)
*
|
2000-05-02 |
2008-12-15 |
Theravance Inc |
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
|
|
ME00555B
(me)
|
2000-05-26 |
2011-12-20 |
Pfizer |
Derivati tropana i njihova primj ena
|
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
|
US7198801B2
(en)
*
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
|
AR030312A1
(es)
*
|
2000-08-03 |
2003-08-20 |
Antares Pharma Ipl Ag |
Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
|
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
NZ526683A
(en)
*
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
|
RU2288921C2
(ru)
*
|
2000-12-19 |
2006-12-10 |
Калифорниа Инститьют оф Текнолоджи |
Композиции, содержащие комплексы включения
|
|
EP1425311A4
(de)
*
|
2001-01-11 |
2004-12-01 |
Eastman Chem Co |
Cyclodextrinsulfonate, gast-einschlusskomplexe, verfahren zu ihrer herstellung und verwandte materialien
|
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
|
ES2283532T3
(es)
|
2001-04-10 |
2007-11-01 |
Pfizer, Inc. |
Derivados de pirazol para tratar el vih.
|
|
UA75135C2
(en)
*
|
2001-05-01 |
2006-03-15 |
Pfizer Prod Inc |
Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
|
|
MY140679A
(en)
|
2001-05-24 |
2010-01-15 |
Avanir Pharmaceuticals |
Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
|
AU2002363959B2
(en)
*
|
2001-12-03 |
2007-12-13 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
|
PL371416A1
(en)
|
2002-02-01 |
2005-06-13 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
CA2475712C
(en)
|
2002-02-11 |
2009-11-24 |
Simon Bailey |
Nicotinamide derivatives useful as pde4 inhibitors
|
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
|
AU2003213210A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
|
BR0307898A
(pt)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
|
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
|
KR100451485B1
(ko)
*
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
IL165258A0
(en)
*
|
2002-05-17 |
2005-12-18 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
ES2340027T3
(es)
|
2002-05-17 |
2010-05-28 |
Celgene Corporation |
Combinaciones para tratar el mieloma multiple.
|
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
|
EP1542668B1
(de)
*
|
2002-08-20 |
2009-04-15 |
Bristol-Myers Squibb Company |
Aripiprazol-komplex-formulierung und verfahren
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
WO2004021985A2
(en)
*
|
2002-09-09 |
2004-03-18 |
Josef Pitha |
Verifiable absorption drug delivery form based on cyclodextrins
|
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
|
RU2359698C2
(ru)
*
|
2002-09-13 |
2009-06-27 |
Сайдекс, Инк. |
Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
|
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
MXPA05003889A
(es)
*
|
2002-10-15 |
2005-06-22 |
Celgene Corp |
Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
|
US7001893B2
(en)
*
|
2002-10-28 |
2006-02-21 |
Council Of Scientific And Industrial Research |
Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
EP1567154A4
(de)
|
2002-11-06 |
2006-05-31 |
Celgene Corp |
Verfahren undzusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zurbehandlung und versorgung von krebs und anderen erkrankungen
|
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
JP2006511606A
(ja)
|
2002-12-13 |
2006-04-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
下部尿路症状を治療するα−2−δリガンド
|
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
EA008829B1
(ru)
*
|
2002-12-17 |
2007-08-31 |
Нэстек Фармасьютикал Кампани Инк. |
Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
|
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
CA2513320C
(en)
*
|
2003-01-14 |
2018-03-27 |
Yeda Research And Development Co. |
Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
|
|
MXPA05007552A
(es)
*
|
2003-01-14 |
2006-05-19 |
Teva Pharma |
Formulaciones parenterales de un peptido para el tratamiento de lupus sistemico eritematoso.
|
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
EP1633770B1
(de)
|
2003-06-13 |
2015-04-29 |
Alnylam Europe AG |
Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
|
|
ATE450535T1
(de)
|
2003-09-03 |
2009-12-15 |
Glaxo Group Ltd |
Neues verfahren zur herstellung von pleuromutilinderivaten
|
|
EA009457B1
(ru)
|
2003-09-03 |
2007-12-28 |
Пфайзер Инк. |
Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
|
|
WO2005023308A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Maxygen Holdings Ltd. |
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
|
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
EP1663398B1
(de)
|
2003-09-12 |
2009-11-25 |
Pfizer Limited |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
|
GEP20084417B
(en)
|
2003-10-03 |
2008-07-10 |
Pfizer |
Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
|
|
NZ546106A
(en)
*
|
2003-10-10 |
2008-10-31 |
Antares Pharma Ipl Ag |
Transdermal pharmaceutical formulation for minimizing skin residues
|
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
|
AU2004288714A1
(en)
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
|
BRPI0416812A
(pt)
|
2003-11-21 |
2007-03-06 |
Combinatorx Inc |
métodos e reagentes para o tratamento de desordens inflamatórias
|
|
CA2548491A1
(en)
*
|
2003-12-08 |
2005-06-23 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic anti-cancer compositions
|
|
PL1691811T3
(pl)
|
2003-12-11 |
2014-12-31 |
Sunovion Pharmaceuticals Inc |
Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
|
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
|
HUE032527T2
(en)
*
|
2003-12-31 |
2017-09-28 |
Cydex Pharmaceuticals Inc |
Sulphoalkyl ether cyclodextrin and corticosteroid inhalation preparation
|
|
WO2005079808A1
(en)
|
2004-01-22 |
2005-09-01 |
Pfizer Limited |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
|
AP2359A
(en)
|
2004-01-22 |
2012-01-30 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases.
|
|
DE602005001929T2
(de)
|
2004-01-22 |
2007-12-06 |
Pfizer Inc. |
Sulfonamidderivate zur behandlung von krankheiten
|
|
CA2825161C
(en)
|
2004-02-24 |
2016-10-04 |
The General Hospital Corporation |
Catalytic radiofluorination
|
|
ATE446581T1
(de)
*
|
2004-03-12 |
2009-11-15 |
Trinity College Dublin |
Magnetoresistives medium
|
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
CA2560510C
(en)
|
2004-03-18 |
2009-10-13 |
Pfizer Inc. |
N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
|
|
BRPI0509019A
(pt)
*
|
2004-03-22 |
2007-08-07 |
Celgene Corp |
métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
|
|
EP1730103B1
(de)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Als adrenozeptor geeignete formamidderivate
|
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
WO2005110408A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
CN103554222A
(zh)
|
2004-04-15 |
2014-02-05 |
欧尼斯治疗公司 |
用于抑制蛋白酶体酶的化合物
|
|
MXPA06012240A
(es)
|
2004-04-23 |
2007-01-31 |
Cydex Inc |
Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
|
|
JP4584987B2
(ja)
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
|
AP2006003771A0
(en)
|
2004-04-30 |
2006-10-31 |
Warner Lambert Co |
Substituted morpholine compounds for the treatmentof central nervous system disorders
|
|
WO2005117911A2
(en)
*
|
2004-05-06 |
2005-12-15 |
Cydex, Inc. |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
|
ES2510840T3
(es)
*
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
|
BRPI0512046A
(pt)
|
2004-06-15 |
2008-02-06 |
Pfizer |
derivados de ácido benzimidazolona carboxìlico
|
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
|
US20070213270A1
(en)
*
|
2004-06-16 |
2007-09-13 |
Costantino Henry R |
Peptide yy formulations having increased stability and resistance to microbial agents
|
|
PT1768966E
(pt)
|
2004-06-17 |
2012-05-23 |
Infinity Discovery Inc |
Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
|
|
MX2007001759A
(es)
|
2004-08-12 |
2007-04-20 |
Pfizer |
Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos.
|
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
MX2007002521A
(es)
*
|
2004-09-03 |
2007-05-09 |
Celgene Corp |
Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
|
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
|
AU2005287865B2
(en)
|
2004-09-21 |
2012-02-16 |
Marshall Edwards, Inc. |
Substituted chroman derivatives, medicaments and use in therapy
|
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
|
EP2436680B1
(de)
|
2004-09-21 |
2016-05-18 |
Marshall Edwards, Inc. |
Chromanderivate, Medikamente und Anwendung in der Therapie
|
|
US20060078955A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Lin-Zhi International |
Method for retrieving delta9-THC from oral fluid
|
|
WO2006046933A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Viktor Olexandrovych Rybchuk |
Sedative and spasmolytic medicinal agent and method for the production thereof (variants)
|
|
KR20070085454A
(ko)
*
|
2004-10-28 |
2007-08-27 |
셀진 코포레이션 |
중추신경계 손상의 치료 및 관리를 위하여 pde4조절제를 사용하는 방법 및 조성물
|
|
EP1809607B1
(de)
|
2004-11-02 |
2008-12-17 |
Pfizer, Inc. |
Sulfonylbenzimidazolderivate
|
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
|
WO2006052922A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
|
WO2006052921A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
|
DE602005026556D1
(de)
*
|
2004-12-07 |
2011-04-07 |
Proteolix Inc |
Zusammensetzung zur proteasomhemmung
|
|
US20060128654A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060128653A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
DE102004060927B3
(de)
*
|
2004-12-17 |
2006-02-16 |
Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg |
Behälter für mindestens einen länglichen Gegenstand
|
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
|
CN101160117A
(zh)
*
|
2005-02-16 |
2008-04-09 |
阿尔扎公司 |
依泊汀-基药物的透皮释放装置和方法
|
|
WO2006089276A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Surface Logix, Inc. |
Pharmacokinetically improved compounds
|
|
WO2006089275A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Surface Logix, Inc. |
Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
|
|
US8703099B2
(en)
|
2005-02-24 |
2014-04-22 |
Dr Pharma Nova, Llc |
Registry method and control system for DEA schedule II-V medicines
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
WO2006100557A1
(en)
|
2005-03-21 |
2006-09-28 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
|
EP2484382A1
(de)
|
2005-03-30 |
2012-08-08 |
Schering Corporation |
Medikament enthaltend einem Phosphodiesterase IV Inhibitor in einer zur Inhalation geeigneten Form
|
|
KR101332869B1
(ko)
*
|
2005-04-15 |
2013-11-25 |
알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 |
항-egfr 치료법에 속발된 피부 발진의 예방 및 치료를위한 비타민 k
|
|
ES2525096T3
(es)
|
2005-04-19 |
2014-12-17 |
Kings College London |
Uso de bip contra la pérdida ósea y osteoporosis
|
|
JP2008538784A
(ja)
*
|
2005-04-24 |
2008-11-06 |
ワイス |
膀胱機能を調節するための方法
|
|
CN101203519A
(zh)
|
2005-05-04 |
2008-06-18 |
辉瑞有限公司 |
用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
|
|
US8669236B2
(en)
*
|
2005-05-12 |
2014-03-11 |
The General Hospital Corporation |
Biotinylated compositions
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
WO2006125642A1
(en)
*
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
|
MX2007015871A
(es)
*
|
2005-06-13 |
2008-03-04 |
Cargill Inc |
Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
|
|
US20090036406A1
(en)
*
|
2005-06-13 |
2009-02-05 |
Takeda Pharmaceutical Company Limited |
Injection
|
|
CA2610000A1
(en)
*
|
2005-06-13 |
2006-12-28 |
Cargill, Incorporated |
Cyclodextrin inclusion complexes and methods of preparing same
|
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
CA2612287C
(en)
|
2005-06-15 |
2011-01-25 |
Pfizer Limited |
Substituted arylpyrazoles for use against parasites
|
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
US20060287301A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mcnair Douglas |
Novel formulations for phenothiazines, including fluphenazine and its derivatives
|
|
KR101299321B1
(ko)
|
2005-06-30 |
2013-08-26 |
셀진 코포레이션 |
4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
|
|
US20070009531A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
|
WO2007008496A1
(en)
*
|
2005-07-06 |
2007-01-18 |
Kanisa Pharmaceuticals, Inc. |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010487A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010486A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010478A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
|
|
US20070010485A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
|
JP5578785B2
(ja)
|
2005-08-31 |
2014-08-27 |
セルジーン コーポレイション |
イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
|
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
US7744904B1
(en)
*
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
|
US20100204178A1
(en)
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
|
AU2013200204B9
(en)
*
|
2005-09-30 |
2015-03-05 |
Lundbeck Llc |
Novel parenteral carbamazepine formulation
|
|
EP1928464B1
(de)
*
|
2005-09-30 |
2014-05-14 |
Lundbeck Inc. |
Neue parenterale carbamazepin-formulierung
|
|
AU2011204957B2
(en)
*
|
2005-10-26 |
2013-12-05 |
Cydex Pharmaceuticals, Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
LT2952197T
(lt)
*
|
2005-10-26 |
2017-08-25 |
Cydex Pharmaceuticals, Inc. |
Sulfonalkileterio ciklodekstrino kompozicijos ir jų gavimo būdai
|
|
RU2417103C2
(ru)
*
|
2005-10-26 |
2011-04-27 |
Сайдекс Фармасьютикалз, Инк. |
Композиции простого сульфоалкилового эфира циклодекстрина и способы их получения
|
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
CN100503647C
(zh)
*
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
|
JP5436860B2
(ja)
*
|
2005-11-09 |
2014-03-05 |
オニキス セラピューティクス, インク. |
酵素阻害のための化合物
|
|
BRPI0618653A2
(pt)
*
|
2005-11-15 |
2011-09-06 |
Baxter Int |
composições compreendendo inibidores da lipoxigenase e ciclodextrina
|
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
|
NZ592293A
(en)
*
|
2005-11-28 |
2012-10-26 |
Verrow Pharmaceuticals Inc |
Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
|
|
MX336930B
(es)
|
2005-11-28 |
2016-02-05 |
Marinus Pharmaceuticals |
Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
|
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
|
CA2642641A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Laekemedel Ab |
Stable corticosteroid mixtures
|
|
RU2008135326A
(ru)
*
|
2006-03-24 |
2010-04-27 |
Вайет (Us) |
Терапевтические композиции для лечения депрессии
|
|
US20070225334A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Methods for treating cognitive and other disorders
|
|
TW200806298A
(en)
*
|
2006-03-24 |
2008-02-01 |
Wyeth Corp |
Methods for modulating bladder function
|
|
MX2008012208A
(es)
*
|
2006-03-24 |
2008-10-02 |
Wyeth Corp |
Metodo para tratar trastornos cognitivos y otros afines.
|
|
AU2007230997A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Treatment of pain
|
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
|
CA2650922C
(en)
|
2006-04-18 |
2015-09-29 |
Ekr Therapeutics, Inc. |
Pre-mixed, ready-to-use pharmaceutical compositions
|
|
CN101426475A
(zh)
*
|
2006-04-21 |
2009-05-06 |
安塔雷斯制药Ipl股份公司 |
使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
|
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
|
CA2654876A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Sunesis Pharmaceuticals, Inc. |
1-8-naphthyridine compounds for the treatment of cancer
|
|
CN101501052A
(zh)
*
|
2006-06-13 |
2009-08-05 |
嘉吉公司 |
大粒子环糊精包合复合物及其制备方法
|
|
MY183014A
(en)
*
|
2006-06-19 |
2021-02-05 |
Onyx Therapeutics Inc |
Compounds for enzyme inhibition
|
|
US9428582B2
(en)
*
|
2006-07-03 |
2016-08-30 |
Genmab A/S |
Method of treating rash in patients undergoing anti-EGFR therapy
|
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
|
US20080063642A1
(en)
|
2006-08-02 |
2008-03-13 |
Adelman Daniel C |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
|
BRPI0714793A2
(pt)
|
2006-08-03 |
2015-06-16 |
Tufts College |
Análogos de niacina não enrubecedores e método de uso dos mesmos.
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
US20080207731A1
(en)
|
2006-08-23 |
2008-08-28 |
Intellect Neurosciences, Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CN100411688C
(zh)
*
|
2006-09-12 |
2008-08-20 |
南京师范大学 |
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
|
|
CN100486645C
(zh)
*
|
2006-09-12 |
2009-05-13 |
南京师范大学 |
含有环糊精紫杉醇包合物的药物组合物及其制备方法
|
|
US8278355B2
(en)
|
2006-09-12 |
2012-10-02 |
Therexcell Pharma Inc. |
Isovaline for treatment of pain
|
|
PT2061458E
(pt)
*
|
2006-09-15 |
2015-03-11 |
Univ Minnesota |
Composições de topiramato e métodos para a sua utilização
|
|
WO2008031439A2
(en)
|
2006-09-15 |
2008-03-20 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
|
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
MX2009000080A
(es)
|
2006-09-21 |
2009-01-23 |
Raqualia Pharma Inc |
Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
|
|
ME02890B
(de)
|
2006-09-26 |
2018-04-20 |
Celgene Corp |
5-substituierte Chinazolinonderivate als Antikrebsmittel
|
|
WO2008045563A2
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
|
RS51647B
(sr)
|
2006-10-18 |
2011-10-31 |
Pfizer Products Inc. |
Jedinjenja biaril etar uree
|
|
CA2666539A1
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
|
JP5401319B2
(ja)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
|
CA2669705A1
(en)
*
|
2006-11-21 |
2008-05-29 |
Novartis Ag |
Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
|
|
WO2008065142A1
(en)
*
|
2006-11-29 |
2008-06-05 |
N.V. Organon |
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
|
|
WO2008067991A2
(en)
*
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
|
JP2010514794A
(ja)
*
|
2006-12-27 |
2010-05-06 |
カーギル インコーポレイテッド |
シクロデキストリン封入複合体および該複合体を調製する方法
|
|
WO2008106721A1
(en)
*
|
2007-03-02 |
2008-09-12 |
University Of Wollongong |
Compositions and methods for delivery of anti-cancer agents
|
|
EP2924113B1
(de)
|
2007-03-02 |
2019-04-10 |
Wyeth LLC |
Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
|
|
WO2011084703A2
(en)
|
2009-12-21 |
2011-07-14 |
Advanced Liquid Logic, Inc. |
Enzyme assays on a droplet actuator
|
|
CA2685331C
(en)
*
|
2007-04-27 |
2016-07-05 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
US20080283693A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Evans Michael J F |
Propulsion apparatus and system
|
|
US8563000B2
(en)
|
2007-05-25 |
2013-10-22 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
|
US12370352B2
(en)
|
2007-06-28 |
2025-07-29 |
Cydex Pharmaceuticals, Inc. |
Nasal and ophthalmic delivery of aqueous corticosteroid solutions
|
|
TWI428132B
(zh)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
|
WO2009018326A2
(en)
*
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Soluble pyrone analogs methods and compositions
|
|
US7893045B2
(en)
*
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
EP2215087B1
(de)
|
2007-09-05 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Xinafoatsalz von n4-(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-yl]-5-fluor-n2-[3-(methylaminocarbonylmethylenoxy)phenyl]-2,4-pyrimidindiamin
|
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
|
KR101593242B1
(ko)
|
2007-09-26 |
2016-02-11 |
셀진 코포레이션 |
6-, 7- 또는 8-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법
|
|
KR20150131405A
(ko)
*
|
2007-10-04 |
2015-11-24 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
MX2010004350A
(es)
*
|
2007-10-22 |
2010-05-19 |
Sunesis Pharmaceuticals Inc |
Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
|
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
|
PE20091432A1
(es)
*
|
2008-02-28 |
2009-10-17 |
Takeda Pharmaceutical |
Composicion farmaceutica
|
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
|
US7635773B2
(en)
*
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
CN102036680A
(zh)
*
|
2008-04-30 |
2011-04-27 |
中子行公司 |
促肾上腺皮质激素释放因子用于治疗癌症的用途
|
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
|
EP2303229A1
(de)
*
|
2008-06-16 |
2011-04-06 |
Debiopharm S.A. |
Konzentrierte oxaliplatin-lösung und herstellungsverfahren dafür
|
|
WO2010014617A1
(en)
*
|
2008-07-28 |
2010-02-04 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
|
EP2328890B1
(de)
|
2008-08-06 |
2012-01-25 |
Pfizer Inc. |
6-substituierte 2-heterocyclylaminopyrazinverbindungen als chk-1-inhibitoren
|
|
US20120039917A1
(en)
|
2008-08-29 |
2012-02-16 |
Alan James Husband |
Immunomodulating activities
|
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
|
JP5675629B2
(ja)
|
2008-10-21 |
2015-02-25 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンを用いた併用療法
|
|
KR20110101135A
(ko)
*
|
2008-10-22 |
2011-09-15 |
노보겐 리서치 피티와이 리미티드 |
예정 세포 사멸을 유도하는 방법
|
|
KR20250016146A
(ko)
|
2008-10-24 |
2025-02-03 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
Dmd를 위한 다중 엑손 스키핑 조성물
|
|
ES2662407T3
(es)
|
2008-10-29 |
2018-04-06 |
Celgene Corporation |
Compuestos isoindolina para uso en el tratamiento del cáncer
|
|
US10463677B2
(en)
|
2008-11-07 |
2019-11-05 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
|
CN104958296B
(zh)
*
|
2008-11-15 |
2017-12-01 |
麦林塔医疗有限公司 |
抗微生物组合物
|
|
JP5621148B2
(ja)
|
2008-11-21 |
2014-11-05 |
ラクオリア創薬株式会社 |
5−ht2b受容体拮抗活性を有する新規ピラゾール−3−カルボキサミド誘導体
|
|
CA2746055C
(en)
|
2008-12-16 |
2016-12-13 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
|
RU2015106671A
(ru)
|
2008-12-31 |
2015-06-27 |
Санесис Фармасьютикалз, Инк. |
Способ получения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты
|
|
NZ593473A
(en)
|
2009-01-12 |
2013-02-22 |
Pfizer Ltd |
Sulfonamide derivatives
|
|
WO2010082813A1
(en)
|
2009-01-13 |
2010-07-22 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Method of treating cancer
|
|
TWI453029B
(zh)
|
2009-01-14 |
2014-09-21 |
Novacta Biosystems Ltd |
去氧艾克特卡丁b(deoxyactagardine b), 包含其之醫藥組合物及其製造方法
|
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
|
JP5731407B2
(ja)
|
2009-02-04 |
2015-06-10 |
ノヴァクタ バイオシステムズ リミティッド |
アクタガルジン誘導体
|
|
CN102387798A
(zh)
|
2009-02-10 |
2012-03-21 |
细胞基因公司 |
供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
|
|
EP2396312A1
(de)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Lenalidomidisotopologe
|
|
CN102388043A
(zh)
|
2009-02-11 |
2012-03-21 |
桑诺维恩药品公司 |
组胺h3反相激动剂和拮抗剂及其使用方法
|
|
RU2558835C2
(ru)
|
2009-02-27 |
2015-08-10 |
Санесис Фармасьютикалз, Инк. |
Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
|
|
JP5749659B2
(ja)
|
2009-03-12 |
2015-07-15 |
ハーゼ インベストメンツ ウーゲー |
Bmpアンタゴニスト感受性が低下した骨形成タンパク質2(bmp2)変異体
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
|
JP5699129B2
(ja)
|
2009-04-14 |
2015-04-08 |
イーライ リリー アンド カンパニー |
造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
|
|
KR20190071006A
(ko)
|
2009-05-13 |
2019-06-21 |
사이덱스 파마슈티칼스, 인크. |
프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
|
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
|
MX388477B
(es)
|
2009-05-29 |
2025-03-12 |
Cydex Pharmaceuticals Inc |
Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
|
|
JP2012528140A
(ja)
|
2009-05-29 |
2012-11-12 |
ファイザー・リミテッド |
新規なグルココルチコイド受容体アゴニスト
|
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
|
EP2440563A1
(de)
|
2009-06-10 |
2012-04-18 |
Sunovion Pharmaceuticals Inc. |
Inverse histamin-h3-agonisten und antagonisten sowie anwendungsverfahren dafür
|
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
BRPI1012262A2
(pt)
|
2009-06-24 |
2016-04-05 |
Stephen Evans Freke |
"método de uso do fator liberador de corticotropina para o tratamento de câncer"
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
|
EA201270283A1
(ru)
|
2009-08-19 |
2012-12-28 |
Рациофарм Гмбх |
Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
|
|
WO2011031818A2
(en)
|
2009-09-11 |
2011-03-17 |
Sepracor Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
|
KR101944119B1
(ko)
|
2009-11-13 |
2019-01-30 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
CA2777719A1
(en)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
|
WO2011064558A2
(en)
|
2009-11-30 |
2011-06-03 |
Cipla Limited |
Pharmaceutical composition
|
|
KR101637246B1
(ko)
|
2009-12-04 |
2016-07-07 |
선오비온 파마슈티컬스 인코포레이티드 |
다환형 화합물 및 이의 사용 방법
|
|
WO2011075699A2
(en)
|
2009-12-18 |
2011-06-23 |
Sunovion Pharmaceuticals Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
|
EP2516395A1
(de)
|
2009-12-22 |
2012-10-31 |
Celgene Corporation |
(methylsulfonyl)-ethylbenzolisoindolinderivate und ihre therapeutische verwendung
|
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
|
NZ601267A
(en)
|
2009-12-23 |
2014-03-28 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
|
EP2521543B1
(de)
|
2010-01-05 |
2016-04-13 |
Celgene Corporation |
Kombination aus einer immunmodulatorischen verbindung und einem artemisinin derivat zur behandlung von krebs
|
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
|
EP2531519A1
(de)
|
2010-02-02 |
2012-12-12 |
Novacta Biosystems Limited |
Lantibiotische salze
|
|
HUE042011T2
(hu)
|
2010-02-11 |
2019-06-28 |
Celgene Corp |
Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
|
|
JP2013520489A
(ja)
|
2010-02-25 |
2013-06-06 |
ファイザー・リミテッド |
ペプチド類似体
|
|
CA2791651C
(en)
|
2010-03-01 |
2019-08-20 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
MX2012010367A
(es)
*
|
2010-03-12 |
2012-11-23 |
Celgene Corp |
Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
|
|
WO2011113015A2
(en)
|
2010-03-12 |
2011-09-15 |
Avi Biopharma, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
AU2011245630B2
(en)
|
2010-04-07 |
2014-07-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
|
CA2805086C
(en)
|
2010-05-13 |
2020-10-20 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
|
CA2837129C
(en)
|
2010-05-26 |
2018-07-03 |
Neurophyxia B.V. |
2-iminobiotin formulations and uses thereof
|
|
US8969349B2
(en)
|
2010-05-26 |
2015-03-03 |
Sunovion Pharmaceuticals Inc. |
Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
|
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
US8937063B2
(en)
|
2010-06-24 |
2015-01-20 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
WO2011163619A1
(en)
|
2010-06-24 |
2011-12-29 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
HRP20211686T1
(hr)
|
2010-06-29 |
2022-03-04 |
Merck Sharp & Dohme Corp. |
Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom
|
|
NL2005052C2
(en)
|
2010-07-07 |
2012-01-10 |
Caroline Haaften |
Xanthanodien for the treatment of cancer.
|
|
EP2590972B1
(de)
|
2010-07-09 |
2015-01-21 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドPfizer Limited |
化合物
|
|
EP2593433B1
(de)
|
2010-07-12 |
2014-11-26 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
|
JP2013531030A
(ja)
|
2010-07-12 |
2013-08-01 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
|
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
|
JP2013532185A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
|
EP2593432B1
(de)
|
2010-07-12 |
2014-10-22 |
Pfizer Limited |
N-sulfonylbenzamidderivate als spannungsgesteuerte natriumkanalhemmer
|
|
EP2409699B1
(de)
|
2010-07-23 |
2014-04-30 |
Combino Pharm, S.L. |
Stabile Voriconazole-enthaltende Zusammensetzungen
|
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
|
ES2591355T3
(es)
|
2010-08-24 |
2016-11-28 |
Algiax Pharmaceuticals Gmbh |
Uso novedoso de leflunomida y malononitrilamidas
|
|
BR112013004275A2
(pt)
|
2010-08-24 |
2016-08-02 |
Imp Innovations Ltd |
glicodendrímeros de polipropileterimina
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
PT2632451T
(pt)
|
2010-10-29 |
2017-12-14 |
Algiax Pharmaceuticals Gmbh |
Utilização de malononitrilamidas na dor neuropática
|
|
EP2635273B1
(de)
|
2010-11-01 |
2020-01-08 |
MEI Pharma, Inc. |
Isoflavonoidzusammensetzungen und verfahren zur krebsbehandlung
|
|
MX343274B
(es)
|
2010-11-15 |
2016-10-31 |
Viiv Healthcare Uk Ltd |
Inhibidores de la replicacion del vih.
|
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
|
CN107141309A
(zh)
|
2011-01-11 |
2017-09-08 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
|
US10463687B2
(en)
|
2011-01-20 |
2019-11-05 |
Cornell University |
Treatments for retinal disorders
|
|
ES2672238T3
(es)
|
2011-01-26 |
2018-06-13 |
Allergan, Inc. |
Composición androgénica para el tratamiento de una afección oftálmica
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
WO2012148548A1
(en)
|
2011-02-25 |
2012-11-01 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
|
WO2012120365A1
(en)
|
2011-03-07 |
2012-09-13 |
Aurobindo Pharma Limited |
Stable pharmaceutical composition comprising ethinyl estradiol
|
|
KR20140019364A
(ko)
|
2011-03-11 |
2014-02-14 |
셀진 코포레이션 |
면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4h)-일)피페리딘-2-6-디온의 용도
|
|
TWI601722B
(zh)
|
2011-03-11 |
2017-10-11 |
西建公司 |
3-(5-胺基-2-甲基-4-氧基-4h-喹唑啉-3-基)-六氫吡啶-2,6-二酮之固體型式及其醫藥組合物及用途
|
|
WO2012123353A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
|
WO2012123406A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of imidazotriazinones
|
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
|
RU2464042C1
(ru)
*
|
2011-03-31 |
2012-10-20 |
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" |
КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
|
|
MX2013011612A
(es)
|
2011-04-05 |
2013-10-17 |
Pfizer Ltd |
Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
|
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
|
WO2012149299A2
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporaiton |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
MX350024B
(es)
|
2011-05-18 |
2017-08-23 |
Raqualia Pharma Inc |
Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
|
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
|
US9480755B2
(en)
*
|
2011-06-03 |
2016-11-01 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
|
KR101731155B1
(ko)
|
2011-06-15 |
2017-04-27 |
신톤 비.브이. |
안정화된 보리코나졸 조성물
|
|
US9056873B2
(en)
|
2011-06-22 |
2015-06-16 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
US9513253B2
(en)
|
2011-07-11 |
2016-12-06 |
Advanced Liquid Logic, Inc. |
Droplet actuators and techniques for droplet-based enzymatic assays
|
|
EP2731959B1
(de)
|
2011-07-13 |
2016-02-03 |
Pfizer Limited |
Enkephalinanaloga
|
|
AU2012284259A1
(en)
|
2011-07-15 |
2014-03-06 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
BR112014002141A2
(pt)
|
2011-08-02 |
2017-02-21 |
Pfizer |
crizotinib para uso no tratamento de câncer
|
|
EP2739274A1
(de)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Behandlung von kognitiver störung
|
|
EP2561863A1
(de)
|
2011-08-22 |
2013-02-27 |
Farmaprojects, S.A.U. |
Pharmazeutische Zusammensetzungen mit Voriconazol
|
|
CA2847842C
(en)
|
2011-09-18 |
2019-12-31 |
Euro-Celtique S.A. |
Pharmaceutical compositions
|
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
|
EA023375B1
(ru)
|
2011-10-26 |
2016-05-31 |
Пфайзер Лимитед |
Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
|
|
ES2748656T3
(es)
|
2011-10-28 |
2020-03-17 |
Inhibitaxin Ltd |
Derivados de piridazina útiles en terapia
|
|
WO2013086441A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human lmna
|
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
|
KR20140107578A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
|
US20140357666A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
EA201491260A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
|
|
JP2015503518A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
|
JP6067031B2
(ja)
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドPfizer Limited |
N−アミノスルホニルベンズアミド
|
|
CA2862076C
(en)
|
2012-01-23 |
2020-04-21 |
Sage Therapeutics, Inc. |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
|
CA2861439C
(en)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
|
CA3132120C
(en)
|
2012-02-08 |
2023-10-24 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
|
EP4083075A1
(de)
|
2012-02-15 |
2022-11-02 |
CyDex Pharmaceuticals, Inc. |
Verfahren zur herstellung von cyclodextrinderivaten
|
|
ES2671608T3
(es)
|
2012-02-21 |
2018-06-07 |
Celgene Corporation |
Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
WO2013130666A1
(en)
*
|
2012-02-28 |
2013-09-06 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
US20150099012A1
(en)
|
2012-03-02 |
2015-04-09 |
Erasmus University Medical Center Rotterdam |
Methods for activating retrovirus in latent infected cells, and compounds for use therein
|
|
EP2822953B9
(de)
|
2012-03-06 |
2017-06-21 |
Pfizer Inc |
Makrocyclische derivate zur behandlung von proliferativen erkrankungen
|
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
|
CN104302183B
(zh)
|
2012-03-30 |
2017-03-01 |
赛博尔泰克股份公司 |
飞燕草色素对抗金黄色葡萄球菌的应用
|
|
CN104302673B
(zh)
|
2012-03-30 |
2017-09-22 |
赛博尔泰克股份公司 |
花青素复合物
|
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
|
US20150133472A1
(en)
|
2012-05-11 |
2015-05-14 |
Cipla Limited |
Pharmaceutical composition
|
|
KR20150020169A
(ko)
|
2012-05-15 |
2015-02-25 |
노파르티스 아게 |
Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
|
|
CA2870339C
(en)
|
2012-05-15 |
2020-06-02 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
US9340537B2
(en)
|
2012-05-15 |
2016-05-17 |
Novatis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
|
PT2861579T
(pt)
|
2012-05-15 |
2018-04-27 |
Novartis Ag |
Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
|
|
WO2013183985A1
(en)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Method of treating cognitive impairment and compounds for use therein
|
|
ES2699810T3
(es)
|
2012-06-29 |
2019-02-12 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
|
|
US9309283B2
(en)
|
2012-07-09 |
2016-04-12 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
|
EP2874606B1
(de)
|
2012-07-18 |
2019-03-06 |
Onyx Therapeutics, Inc. |
Liposomale zusammensetzungen von proteasomhemmern auf epoxyketonbasis
|
|
US9221788B2
(en)
|
2012-08-09 |
2015-12-29 |
Celgene Corporation |
Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
|
KR102266510B1
(ko)
|
2012-08-09 |
2021-06-16 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
|
HRP20200836T1
(hr)
|
2012-08-09 |
2020-08-07 |
Celgene Corporation |
Liječenje bolesti povezanih s imunitetom i upalnih bolesti
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
WO2014031792A2
(en)
|
2012-08-21 |
2014-02-27 |
Sage Therapeutics |
Methods of treating epilepsy or tatus epilepticus
|
|
WO2014036427A1
(en)
|
2012-08-31 |
2014-03-06 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
|
WO2014039831A1
(en)
|
2012-09-07 |
2014-03-13 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
|
|
CN104797256A
(zh)
|
2012-09-10 |
2015-07-22 |
细胞基因公司 |
用于治疗局部晚期乳腺癌的方法
|
|
EP2897950A1
(de)
|
2012-09-18 |
2015-07-29 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl-)amino-pyrimidin-5-carboxamide als milz-tyrosinkinasehemmer
|
|
US20150239842A1
(en)
|
2012-09-28 |
2015-08-27 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
|
WO2014053965A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Tropomyosin-related kinase inhibitors
|
|
US9163021B2
(en)
|
2012-10-04 |
2015-10-20 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
|
MX360192B
(es)
|
2012-10-22 |
2018-10-24 |
Cydex Pharmaceuticals Inc |
Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
|
|
SG11201502884TA
(en)
|
2012-11-08 |
2015-05-28 |
Pfizer |
Heteroaromatic compounds as dopamine d1 ligands
|
|
BR112015010620A2
(pt)
|
2012-11-08 |
2017-07-11 |
Pfizer |
compostos heteroaromáticos e seus usos como ligantes de dopamina d1
|
|
JP2015536991A
(ja)
|
2012-11-09 |
2015-12-24 |
セルジーン コーポレイション |
骨量の減少の治療方法
|
|
US9925274B2
(en)
|
2012-11-15 |
2018-03-27 |
Sapiotec Gmbh |
Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
|
|
HK1208457A1
(en)
|
2012-11-21 |
2016-03-04 |
拉夸里亚创药株式会社 |
Polymorph forms
|
|
EP2925762B1
(de)
|
2012-11-29 |
2017-07-05 |
Sunovion Pharmaceuticals Inc. |
Triazolo-pyrazin-derivate zur behandlung von erkrankungen des zentralen nervensystems
|
|
DK2925327T3
(da)
|
2012-11-30 |
2024-03-25 |
Univ California |
Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
|
|
WO2014087298A1
(en)
|
2012-12-03 |
2014-06-12 |
Pfizer Inc. |
Novel selective androgen receptor modulators
|
|
HK1215392A1
(zh)
|
2012-12-11 |
2016-08-26 |
赛博尔泰克股份公司 |
用於对抗黑色素瘤细胞的飞燕草素
|
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
|
EP2935584A1
(de)
|
2012-12-20 |
2015-10-28 |
Sarepta Therapeutics, Inc. |
Verbesserte exon-skipping-zusammensetzungen zur behandlung von muskeldystrophie
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
WO2014106238A1
(en)
|
2012-12-31 |
2014-07-03 |
Fang, Qun, Kevin |
Heterocyclic compounds and methods of use thereof
|
|
EP2943201B2
(de)
|
2013-01-14 |
2020-07-29 |
Deuterx, LLC |
3-(5-substituierte 4-oxochinazolin-3(4h) -yl)-3-deutero-piperidin-2,6-dionderivate
|
|
WO2014116573A1
(en)
|
2013-01-22 |
2014-07-31 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
AP2015008618A0
(en)
|
2013-02-19 |
2015-07-31 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
|
PT3431475T
(pt)
|
2013-02-21 |
2021-05-13 |
Pfizer |
Formas sólidas de um inibidor de cdk4/6 seletivo
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
CN105378081B
(zh)
|
2013-03-14 |
2019-06-14 |
萨勒普塔医疗公司 |
用于治疗肌营养不良的外显子跳跃组合物
|
|
SMT201900139T1
(it)
|
2013-03-14 |
2019-05-10 |
Sarepta Therapeutics Inc |
Composizioni di salto dell'esone per il trattamento della distrofia muscolare
|
|
EP3693021A1
(de)
*
|
2013-03-14 |
2020-08-12 |
Allergan, Inc. |
Zusammensetzung mit verzögerter freisetzung und verfahren zur stabilisierung von proteinen während des herstellungsverfahrens
|
|
EP3662912B1
(de)
|
2013-03-15 |
2025-12-03 |
Sarepta Therapeutics, Inc. |
Verbesserte eteplirsen dosierungen zur behandlung von duchenne muskeldystrophie
|
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
|
JP6469077B2
(ja)
|
2013-04-02 |
2019-02-13 |
セルジーン コーポレイション |
4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
|
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
|
DK3013813T3
(da)
|
2013-06-27 |
2019-06-03 |
Pfizer |
Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
|
|
CN105517541A
(zh)
|
2013-07-08 |
2016-04-20 |
艾伯维公司 |
包含阿曲生坦的稳定化药物剂型
|
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
WO2015092610A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
|
US9371321B2
(en)
|
2014-01-09 |
2016-06-21 |
Astrazeneca Ab |
Azaindole derivatives
|
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
|
CN103694376B
(zh)
*
|
2014-01-10 |
2016-04-13 |
凯莱英医药集团(天津)股份有限公司 |
一种制备磺丁基醚-β-环糊精的方法
|
|
ES2831326T3
(es)
|
2014-01-15 |
2021-06-08 |
Poxel Sa |
Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物
|
|
EP3094629B1
(de)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idin-derivate und zusammensetzungen davon zur hemmung der aktivität von shp2
|
|
EP2913050A1
(de)
|
2014-02-28 |
2015-09-02 |
SapioTec GmbH |
Verfahren zur Herstellung eines Flurankomplexes
|
|
EP3119744B1
(de)
|
2014-03-18 |
2019-03-06 |
Algiax Pharmaceuticals GmbH |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamidderivate
|
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
|
PE20170008A1
(es)
|
2014-04-25 |
2017-03-17 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
|
|
TN2016000447A1
(en)
|
2014-04-25 |
2018-04-04 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands.
|
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
|
US9856263B2
(en)
|
2014-04-28 |
2018-01-02 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
|
EP3137469B1
(de)
|
2014-04-28 |
2019-10-09 |
Pfizer Inc |
Heterocyclische verbindungen und deren verwendung als dopamin-d1-liganden
|
|
EP3139924A4
(de)
|
2014-05-06 |
2018-03-07 |
Anthony G. Visco |
Verfahren zur behandlung oder prävention von vorzeitigen wehen
|
|
EP3140298A1
(de)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-assoziierte kinaseinhibitoren
|
|
AU2015260905A1
(en)
|
2014-05-14 |
2016-12-01 |
Pfizer Inc. |
Pyrazolopyridines and pyrazolopyrimidines
|
|
PL3143019T3
(pl)
|
2014-05-15 |
2021-03-22 |
Pfizer Inc. |
Krystaliczna postać 6-[(4R)-4-metylo-1,2-dioksydo-1,2,6-tiadiazynan-2-ylo]izochinolino-1-karbonitrylu
|
|
EP3145926B1
(de)
|
2014-05-20 |
2019-07-03 |
RaQualia Pharma Inc. |
Benzisoxazolderivatsalz
|
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
|
JP2017516803A
(ja)
|
2014-05-30 |
2017-06-22 |
ファイザー・インク |
ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
|
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
|
MD4820C1
(ro)
|
2014-06-17 |
2023-03-31 |
Pfizer Inc. |
Compuşi dihidroizochinolinonici substituiţi
|
|
NZ725354A
(en)
|
2014-06-18 |
2018-05-25 |
Elanco Us Inc |
Transdermal formulations of pergolide and uses thereof
|
|
EP3827836A1
(de)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
|
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
|
TWI568365B
(zh)
*
|
2014-07-22 |
2017-02-01 |
蘇廷弘 |
抑菌複合物及其製造方法
|
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
|
JP6914188B2
(ja)
*
|
2014-08-22 |
2021-08-04 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
|
|
PL3182996T3
(pl)
|
2014-08-22 |
2023-04-17 |
Celgene Corporation |
Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
|
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
|
EP3233829B1
(de)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidin und triazinderivate und deren verwendung als axl-inhibitoren
|
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
|
UY36530A
(es)
|
2015-01-22 |
2016-08-31 |
Phytoplant Res S L |
Métodos para purificar cannabinoides, composiciones y kits de estos
|
|
DK3050574T3
(da)
|
2015-01-28 |
2020-01-20 |
Univ Bordeaux |
Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
|
|
US10980774B2
(en)
|
2015-02-02 |
2021-04-20 |
Mei Pharma, Inc. |
Combination therapies
|
|
US20160228454A1
(en)
|
2015-02-06 |
2016-08-11 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
|
|
ES2792899T3
(es)
|
2015-02-24 |
2020-11-12 |
Pfizer |
Derivados de nucleósidos sustituidos útiles como agentes anticancerosos
|
|
CA2979527A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
|
|
JP6971963B2
(ja)
|
2015-03-19 |
2021-11-24 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
シリマリンおよびスルホアルキルエーテルシクロデキストリンを含有する組成物ならびにそれを使用する方法
|
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
|
NL2014614B1
(en)
|
2015-04-10 |
2017-01-25 |
Pld Biochemistry B V |
Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
|
|
WO2016195476A1
(en)
|
2015-05-29 |
2016-12-08 |
Erasmus University Medical Center Rotterdam |
Treatment of cardiac arrhythmias
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
|
EP3316888A1
(de)
|
2015-07-02 |
2018-05-09 |
Celgene Corporation |
Kombinationstherapie zur behandlung von hämatologischen krebserkrankungen und soliden tumoren
|
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
|
BR112018000041A2
(pt)
|
2015-07-31 |
2018-09-04 |
Pfizer Inc. |
Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
|
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
WO2017093912A1
(en)
|
2015-11-30 |
2017-06-08 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations for intravenous injection of danirixin
|
|
WO2017098367A1
(en)
|
2015-12-10 |
2017-06-15 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
|
EA039213B1
(ru)
|
2015-12-24 |
2021-12-17 |
Такеда Фармасьютикал Компани Лимитед |
Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
|
EP3399968B8
(de)
|
2016-01-07 |
2021-12-01 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
|
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
|
SG11201805202VA
(en)
|
2016-01-15 |
2018-07-30 |
Pfizer |
6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
|
|
AU2017214669B2
(en)
|
2016-02-04 |
2022-01-13 |
Czap Research And Development, Llc |
Controlled-release and stratified cyclodextrin inclusion complex vehicles
|
|
HK1258616A1
(zh)
|
2016-03-08 |
2019-11-15 |
Sage Therapeutics, Inc. |
神经活性类固醇、组合物、及其用途
|
|
EP3426772A4
(de)
|
2016-03-09 |
2019-08-28 |
Beijing Percans Oncology Co. Ltd. |
Tumorzellsuspensionskulturen und zugehörige verfahren
|
|
PL3436447T3
(pl)
*
|
2016-03-31 |
2021-12-27 |
Takeda Pharmaceutical Company Limited |
Kompleksy triazolonu izochinolinylowego
|
|
MX2018013157A
(es)
|
2016-04-29 |
2019-05-23 |
Sarepta Therapeutics Inc |
Analogos de oligonucleotidos dirigidos a lmna humana.
|
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
|
RU2021106500A
(ru)
|
2016-06-14 |
2021-04-16 |
Новартис Аг |
Соединения и композиции для подавления активности shp2
|
|
TW201811807A
(zh)
|
2016-06-30 |
2018-04-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
CA3031413A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal compounds and uses thereof
|
|
SG11201900687VA
(en)
|
2016-07-29 |
2019-02-27 |
Sunovion Pharmaceuticals Inc |
Compounds and compositions and uses thereof
|
|
US20190270778A1
(en)
|
2016-07-29 |
2019-09-05 |
Pfizer Inc. |
Cyclic Peptides As C5a Receptor Antagonists
|
|
CN116283877A
(zh)
|
2016-07-29 |
2023-06-23 |
赛诺维信制药公司 |
化合物、组合物及其用途
|
|
EP4233861A3
(de)
|
2016-08-11 |
2023-10-11 |
Ovid Therapeutics, Inc. |
Zusammensetzungen zur behandlung von essentiellem tremor
|
|
US10233188B2
(en)
|
2016-08-15 |
2019-03-19 |
Pfizer Inc. |
CDK2/4/6 inhibitors
|
|
MX387820B
(es)
*
|
2016-08-19 |
2025-03-18 |
Foresee Pharmaceuticals Co Ltd |
Composición farmacéutica y métodos de usos.
|
|
US10532102B2
(en)
|
2016-08-19 |
2020-01-14 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
WO2018068832A1
(en)
|
2016-10-11 |
2018-04-19 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
|
AU2017361875A1
(en)
|
2016-11-18 |
2019-06-06 |
Aicuris Gmbh & Co. Kg |
Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
|
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
|
LT3554553T
(lt)
|
2016-12-19 |
2022-08-25 |
Sarepta Therapeutics, Inc. |
Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
|
|
RS63621B1
(sr)
|
2016-12-19 |
2022-10-31 |
Sarepta Therapeutics Inc |
Oligomerni konjugati za preskakanje egzona za mišićnu distrofiju
|
|
PL3554554T3
(pl)
|
2016-12-19 |
2022-12-19 |
Sarepta Therapeutics, Inc. |
Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
|
|
EP3558950B1
(de)
|
2016-12-20 |
2023-05-10 |
Oligomerix, Inc. |
Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
|
|
CA3047729A1
(en)
|
2016-12-20 |
2018-06-28 |
Oligomerix, Inc. |
Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
|
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
|
SG11201906427QA
(en)
|
2017-01-23 |
2019-08-27 |
Pfizer |
Heterocyclic spiro compounds as magl inhibitors
|
|
US10434095B2
(en)
|
2017-01-27 |
2019-10-08 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
WO2018151861A1
(en)
|
2017-02-16 |
2018-08-23 |
Sunovion Pharamaceuticials Inc. |
Methods of treating schizophrenia
|
|
CN110520127B
(zh)
|
2017-03-26 |
2023-05-16 |
武田药品工业株式会社 |
作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
|
|
AU2018256435B2
(en)
|
2017-04-20 |
2025-03-13 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
|
MX2019013053A
(es)
|
2017-05-03 |
2020-02-07 |
Cydex Pharmaceuticals Inc |
Composicion que contiene ciclodextrina y busulfan.
|
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
|
JP7296954B2
(ja)
|
2017-06-22 |
2023-06-23 |
キュラデブ・ファーマ・リミテッド |
ヒトstingの小分子調節因子
|
|
FI3644999T3
(fi)
*
|
2017-06-30 |
2023-03-19 |
Celgene Corp |
2-(4-kloorifenyyli)-n-((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-5-yyli)metyyli)-2,2-difluoriasetamidin koostumukset ja menetelmät sen käyttämiseksi
|
|
ES3000461T3
(en)
|
2017-07-11 |
2025-02-28 |
Gilead Sciences Inc |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
JP7191085B2
(ja)
|
2017-08-02 |
2022-12-16 |
サノビオン ファーマシューティカルズ インク |
イソクロマン化合物およびその使用
|
|
KR102782200B1
(ko)
|
2017-08-30 |
2025-03-17 |
에이제이 사이언시즈 (이씽) 코., 엘티디 |
인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
|
|
CN111201223B
(zh)
|
2017-09-11 |
2024-07-09 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
|
US20210145852A1
(en)
|
2017-09-28 |
2021-05-20 |
Sarepta Therapeutics, Inc. |
Combination Therapies for Treating Muscular Dystrophy
|
|
US20200254002A1
(en)
|
2017-09-28 |
2020-08-13 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3746419A1
(de)
|
2018-01-29 |
2020-12-09 |
Phytoplant Research S.L. |
Verfahren zur reinigung von cannabinoiden unter verwendung von flüssig-flüssigchromatografie
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
|
TWI741268B
(zh)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
|
|
HUE070823T2
(hu)
|
2018-04-26 |
2025-07-28 |
Pfizer |
2-amino-piridin- vagy 2-amino-pirimidin-származékok ciklinfüggõ kináz gátlószereiként
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
EP3801481A1
(de)
|
2018-05-30 |
2021-04-14 |
Convert Pharmaceuticals SA |
Prodrugs und medizinische verwendungen davon
|
|
WO2019232201A1
(en)
|
2018-06-01 |
2019-12-05 |
Bayer Cropscience Lp |
Stabilized fungicidal composition comprising cyclodextrin
|
|
EP3806868A4
(de)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
|
AU2019304198A1
(en)
|
2018-07-19 |
2021-02-04 |
Pfizer Inc. |
Heterocyclic spiro compounds as MAGL inhibitors
|
|
CN112512559B
(zh)
|
2018-07-26 |
2025-02-28 |
Atyr医药公司 |
用于治疗nrp2相关疾病的组合物和方法
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
KR20210056379A
(ko)
|
2018-09-04 |
2021-05-18 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
살바이러스 나노입자 및 인플루엔자 바이러스에 대한 이의 용도
|
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
|
TWI736037B
(zh)
|
2018-11-29 |
2021-08-11 |
美商輝瑞股份有限公司 |
化學化合物
|
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
|
ES3041602T3
(en)
|
2018-12-10 |
2025-11-13 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
|
CN113412330A
(zh)
|
2018-12-13 |
2021-09-17 |
萨勒普塔医疗公司 |
用于肌营养不良的外显子跳跃寡聚物缀合物
|
|
US12377076B2
(en)
|
2018-12-18 |
2025-08-05 |
Purdue Pharma L.P. |
Compounds for treating lymphoma or a T-cell malignant disease
|
|
AU2020204925B2
(en)
|
2019-01-03 |
2025-11-20 |
Cyclarity Therapeutics, Inc. |
Cyclodextrin dimers, compositions thereof, and uses thereof
|
|
WO2020141226A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of torsemide and uses thereof
|
|
CN113271923B
(zh)
|
2019-01-04 |
2025-05-13 |
Sq创新股份公司 |
呋塞米的药物组合物及其用途
|
|
US20210387992A1
(en)
|
2019-01-23 |
2021-12-16 |
Pfizer Inc. |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
|
EP3917913A2
(de)
|
2019-01-31 |
2021-12-08 |
Pfizer Inc. |
3-carbonylamino-5-cyclopentyl-1h-pyrazol-verbindung mit hemmender wirkung gegenüber cdk2
|
|
CN113395958A
(zh)
|
2019-02-01 |
2021-09-14 |
H.隆德贝克有限公司 |
基本上无10-溴-卡马西平的可注射卡马西平组合物
|
|
CN113784755B
(zh)
|
2019-03-14 |
2024-05-10 |
赛诺维信制药公司 |
异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
|
|
TW202102498A
(zh)
|
2019-03-22 |
2021-01-16 |
日商武田藥品工業股份有限公司 |
作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
|
|
MA55515A
(fr)
|
2019-03-28 |
2022-02-09 |
Sarepta Therapeutics Inc |
Procédés de traitement de la dystrophie musculaire avec casimersen
|
|
EP3955966A1
(de)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Zusammensetzungen zur behandlung von muskeldystrophie
|
|
SG11202111717XA
(en)
|
2019-04-29 |
2021-11-29 |
Solent Therapeutics Llc |
3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
|
|
US20220296633A1
(en)
|
2019-06-19 |
2022-09-22 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
WO2021014415A2
(en)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
|
EP4009982A4
(de)
|
2019-08-05 |
2023-08-09 |
Marinus Pharmaceuticals, Inc. |
Ganaxolon zur verwendung bei der behandlung von status epilepticus
|
|
WO2021026310A1
(en)
|
2019-08-06 |
2021-02-11 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
AR119971A1
(es)
|
2019-09-16 |
2022-01-26 |
Takeda Pharmaceuticals Co |
Derivados de piridazin-3(2h)-ona fusionados con azol
|
|
KR20220070254A
(ko)
|
2019-09-25 |
2022-05-30 |
화이자 인코포레이티드 |
Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
|
|
US20210145816A1
(en)
|
2019-11-15 |
2021-05-20 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
|
|
US20230023070A1
(en)
|
2019-12-02 |
2023-01-26 |
Celegene Corporation |
Therapy for the Treatment of Cancer
|
|
JP7780431B2
(ja)
|
2019-12-06 |
2025-12-04 |
マリナス ファーマシューティカルズ, インコーポレイテッド |
結節性硬化症の治療での使用のためのガナキソロン
|
|
CN115151304B
(zh)
|
2020-02-12 |
2025-02-11 |
库拉德夫制药私人有限公司 |
小分子干扰素基因刺激因子(sting)拮抗剂
|
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
|
CN115698004A
(zh)
|
2020-05-01 |
2023-02-03 |
辉瑞公司 |
作为hpk1抑制剂的氮杂内酰胺化合物
|
|
CN115515933A
(zh)
|
2020-05-04 |
2022-12-23 |
武田药品工业株式会社 |
经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
|
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
|
US11292765B2
(en)
|
2020-06-30 |
2022-04-05 |
Field Trip Psychedelics Inc. |
Tryptamine prodrugs
|
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
|
CA3195121A1
(en)
|
2020-10-09 |
2022-04-14 |
Robert A. Volkmann |
Heteroaryl amide inhibitors of cd38
|
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
|
EP4313151A1
(de)
|
2021-03-31 |
2024-02-07 |
Sevenless Therapeutics Limited |
Sos1-inhibitoren und ras-inhibitoren zur verwendung bei der behandlung von schmerzen
|
|
CN117545751A
(zh)
|
2021-04-07 |
2024-02-09 |
生命爱科 |
作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
|
|
KR20240027048A
(ko)
|
2021-06-26 |
2024-02-29 |
어레이 바이오파마 인크. |
Her2 돌연변이 억제제
|
|
EP4380941A1
(de)
|
2021-08-05 |
2024-06-12 |
Bristol-Myers Squibb Company |
Tricyclische kondensierte pyrimidinverbindungen zur verwendung als her2-inhibitoren
|
|
AU2022325543A1
(en)
|
2021-08-11 |
2024-02-15 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
|
TW202321231A
(zh)
|
2021-08-11 |
2023-06-01 |
印度商裘拉德製藥私人有限公司 |
作為sting拮抗劑之小分子尿素衍生物
|
|
EP4162933A1
(de)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
|
|
FI4441052T3
(fi)
|
2021-12-01 |
2026-02-17 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Yhdisteitä
|
|
AU2023235302A1
(en)
|
2022-03-17 |
2024-10-24 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
CA3255222A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
|
CA3263179A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
|
AR130151A1
(es)
|
2022-08-10 |
2024-11-06 |
Takeda Pharmaceuticals Co |
Compuesto heterocíclico
|
|
CA3268810A1
(en)
|
2022-09-28 |
2024-04-04 |
Altos Labs, Inc. |
EXPRESSION OF REGENERATION FACTORS IN AGED/SENESCENT CELLS
|
|
EP4598538A1
(de)
|
2022-10-05 |
2025-08-13 |
Sevenless Therapeutics Limited |
Neue schmerzbehandlungen
|
|
IL320683A
(en)
|
2022-11-15 |
2025-07-01 |
Curadev Pharma Ltd |
Pyridone and pyrimidinone inhibitors of hematopoietic progenitor cell kinase 1
|
|
AU2023420130A1
(en)
|
2022-12-30 |
2025-08-14 |
Cornell University |
Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
|
|
EP4655303A1
(de)
|
2023-01-26 |
2025-12-03 |
Takeda Pharmaceutical Company Limited |
1-amino-4-phenylphthalazinderivate zur behandlung neurodegenerativer erkrankungen
|
|
AU2024255473A1
(en)
|
2023-04-14 |
2025-10-16 |
Takeda Pharmaceutical Company Limited |
Pyrazolopyrimidine derivatives as inhibitors of nlrp3
|
|
WO2024231293A1
(en)
|
2023-05-05 |
2024-11-14 |
Euro-Celtique S.A. |
Combinations for treating cancer
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025074305A1
(en)
|
2023-10-04 |
2025-04-10 |
Takeda Pharmaceutical Company Limited |
N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
GB202319181D0
(en)
|
2023-12-14 |
2024-01-31 |
Imperial College Innovations Ltd |
Nora Inhibitors
|
|
WO2025137437A1
(en)
|
2023-12-21 |
2025-06-26 |
Pfizer Inc. |
Solid forms of a gabaa receptor modulator and methods of its use
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025231370A1
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
Inhibitors of cd38
|
|
WO2025229624A2
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
New cd38 inhibitors
|
|
WO2025233837A1
(en)
|
2024-05-07 |
2025-11-13 |
Takeda Pharmaceutical Company Limited |
4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
|
|
US12383633B1
(en)
|
2024-10-01 |
2025-08-12 |
Zymeron Corporation |
Injectable formulations of PARP inhibitors and uses thereof
|